LPS and Metabolic Endotoxemia, Explained: What the Human Evidence Actually Shows (2026)
Share
By Brandon, founder of Ozzi · Published August 3, 2026 · Updated October 31, 2026
What is LPS, and what does "metabolic endotoxemia" actually mean?
LPS (lipopolysaccharide) is a large molecule that makes up the outer membrane of gram-negative bacteria, and metabolic endotoxemia is the hypothesis that a small amount of it, roughly 2 to 3 times normal levels, drifts across the gut wall on a regular basis and keeps your immune system mildly annoyed. Your colon is full of gram-negative bacteria. Billions of them, right now, doing useful work.
Your immune system takes LPS seriously because it's a reliable signature of bacterial presence. A receptor called TLR4 recognizes it and starts an inflammatory response.
The proposed downstream result is chronic low-grade inflammation, insulin resistance, and weight gain.
The proposed pathway, simplified. Every arrow in this diagram is better supported in rodents than in people.
Where did this idea come from?
The idea of metabolic endotoxemia came mostly from one paper, a mouse study that Patrice Cani and colleagues published in Diabetes in 2007, titled "Metabolic endotoxemia initiates obesity and insulin resistance."
That study was done in mice. Researchers fed mice a high-fat diet for 4 weeks and watched plasma LPS climb 2 to 3 fold. Then they pumped LPS directly under the skin of a second group of mice for 4 weeks and produced similar weight gain, fatty liver, and liver insulin resistance.
Does the human evidence hold up?
The human evidence for metabolic endotoxemia partly holds up, and a 2025 critical review in the American Journal of Physiology argues the case is a lot shakier than the field assumes.
Bandy Chen and Laurent Gautron went through the literature and raised two problems. First, methodological: it's still unclear whether meaningful amounts of bioactive gut-derived LPS actually reach human blood. Second, theoretical: several parts of the hypothesis don't cohere well with each other.
They also point at an awkward finding. When lean and obese people are given an acute LPS challenge, they respond about the same, with cortisol as the main difference. If people with obesity were chronically marinating in low-level endotoxin, you'd expect their immune systems to look either tolerant or sensitized. Mostly they don't.
That's a real problem for the strong version of the theory. It's not a knockout blow, and the authors don't present it as one, but it's the kind of detail that never makes it into a supplement ad.
Why is blood endotoxin so hard to measure?
Blood endotoxin is hard to measure because the standard test is genuinely bad at this job: blood proteins and lipoproteins interfere with the reaction, and results swing between labs.
Endotoxin in blood is usually measured with the Limulus amebocyte lysate assay, which uses clotting factors from horseshoe crab blood. It was designed to check whether medical equipment is contaminated, and it's excellent at that.
So a lot of researchers use a proxy instead: LBP, or lipopolysaccharide binding protein. Your liver makes more of it when there's more LPS around, so it's a smoother, more stable signal.
A 2025 systematic review and meta-analysis pooled 13 studies and found LBP levels significantly higher in people with metabolic syndrome than in people without it. Encouraging, until you read the authors' own caveats. Heterogeneity was extreme (I² of 99.7%), individual studies swung the pooled result around, and the Egger test flagged considerable publication bias. Their own conclusion asks readers to interpret the finding with caution.
Does a high-fat meal really raise endotoxin in people?
A high-fat diet did raise fasting endotoxin in adults with obesity, with no significant change in normal-weight adults, in a 2025 randomized crossover trial that put 32 people aged 50 to 79 on a 40% fat diet and a 20% fat diet for 5 days each.
The results, in humans, not mice:
- After a mixed meal, the rise in endotoxin was 1.8 times higher in participants with obesity than in normal-weight participants.
- Fasting endotoxin was higher after the high-fat diet than the low-fat diet in the obesity group (+0.13 EU/mL), with no significant change in the normal-weight group.
- Serum zonulin was higher after the high-fat diet and higher overall in the obesity group.
- Gram-negative bacteria in stool barely moved.
That last bullet is the interesting one. The authors concluded the endotoxin rise looked like a permeability effect rather than a change in which bacteria were present. The bugs stayed the same. What changed was how much got across.
One caveat on that zonulin result: zonulin as a barrier marker has serious credibility problems of its own, which I dug into in the zonulin test truth. The endotoxin measurements here stand on their own, though.
Is all LPS the same?
LPS is not all the same: in a 2021 mouse study, the source species changed the effect, with LPS from one bacterium damaging the gut barrier and an equal dose from another counteracting that damage.
Which means "your endotoxin level is high" may be close to meaningless without knowing which bacteria it came from. Again, mice. But it's a strong argument that the whole one-number framing is too crude.
| Claim you'll see online | Evidence type | How solid |
|---|---|---|
| LPS infusion causes weight gain and insulin resistance | Rodent (Cani 2007) | Strong in mice, untested as an intervention in people |
| High-fat meals raise blood endotoxin | Human RCT crossover (2025) | Reasonable, effect larger in people with obesity |
| Endotoxin markers are higher in metabolic syndrome | Human meta-analysis (2025) | Associational, heavy heterogeneity and publication bias |
| All circulating LPS is harmful | Rodent (Cell Reports 2021) | Contradicted, source species changes the effect |
| Bioactive LPS routinely circulates in healthy people | Critical review (2025) | Actively disputed |
| A supplement can "flush LPS" from your blood | None | Marketing |
So what actually supports your gut barrier?
What the research supports for your gut barrier is keeping the cells that line your colon fed: those cells preferentially burn butyrate, and fiber feeds the bacteria that make it.
There's no product that pulls endotoxin out of your bloodstream, and anyone selling you one is inventing a mechanism.
I went deeper on feeding those cells in how to increase butyrate naturally and prebiotic fiber and appetite.
For the fuller picture on barrier function, I'd start with leaky gut and inflammation and how to improve gut barrier function naturally. If you want the appetite side of the story, gut health and GLP-1 and the gut-brain axis cover how this system talks to your brain.
What does this mean for Ozzi?
500mg L-Lysine Butyrate (BIOMEnd) delivers butyrate directly. Butyrate is the primary energy source for the cells lining your colon. That's the claim, and it's a structure/function claim, not a treatment claim.
What I'm not going to tell you is that Ozzi lowers your endotoxin levels, seals anything, or reverses metabolic endotoxemia. There are zero human trials on L-Lysine Butyrate, none on Ozzi as a formula, and given how unreliable endotoxin measurement is in humans, I'd be skeptical of anyone who claims otherwise about their product either.
Ozzi is built for cravings and food noise. Butyrate is in there for gut support, and the honest version of that story is the one above. If you want the appetite mechanism instead, what is GLP-1 is the better starting point.
Frequently asked questions
Is metabolic endotoxemia a real diagnosis?
Metabolic endotoxemia is not a real diagnosis. It's a research hypothesis, not a clinical condition. No doctor will diagnose you with it, and there's no established treatment protocol.
Does butyrate help with LPS?
Butyrate is the primary energy source for colonocytes, the cells lining your colon, which is a well-established piece of cell biology. Most of the specific work connecting butyrate to barrier function and endotoxin comes from animal and cell studies. I wouldn't extrapolate it to a human endotoxin claim.
About the author
Brandon is the founder of Ozzi. He started the company after a year of reading metabolic research trying to figure out why his own cravings owned him after 8pm. He writes every article on this blog himself and reads the papers he cites, including the ones that complicate his own product's story.

Butyrate you can actually drink
Ozzi Crave Crusher
500mg of BIOMEnd L-lysine butyrate per stick, alongside allulose, konjac fiber, chromium and African mango. No capsules, no caffeine, and no butyric acid smell.
See what's in it →References
- Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761-72. Rodent study. https://doi.org/10.2337/db06-1491
- Chen B, Gautron L. Gut-derived lipopolysaccharides and metabolic endotoxemia: a critical review. Am J Physiol Endocrinol Metab. 2025;329(5):E746-E754. Critical review. https://doi.org/10.1152/ajpendo.00355.2025
- Ogilvie AR, Onishi JC, Schlussel Y, et al. Short-term high fat diet-induced metabolic endotoxemia in older individuals with obesity: a randomized crossover study. Am J Clin Nutr. 2025;122(2):601-611. Human randomized crossover trial. https://doi.org/10.1016/j.ajcnut.2025.06.001
- Mazaheri-Tehrani S, Rezaei F, Heidari-Hasanabadi S, et al. Serum lipopolysaccharide binding protein (LBP) and metabolic syndrome: a systematic review and meta-analysis. Diabetol Metab Syndr. 2025;17(1):268. Human meta-analysis. https://doi.org/10.1186/s13098-025-01847-w
- Anhê FF, Barra NG, Cavallari JF, Henriksbo BD, Schertzer JD. Metabolic endotoxemia is dictated by the type of lipopolysaccharide. Cell Rep. 2021;36(11):109691. Rodent study. https://doi.org/10.1016/j.celrep.2021.109691
- Rauch CE, Henningsen K, Martinez I, et al. The effects of prebiotic supplementation on markers of exercise-induced gastrointestinal syndrome in response to exertional heat stress. Int J Sport Nutr Exerc Metab. 2025;35(4):273-290. Human randomized trial. https://doi.org/10.1123/ijsnem.2024-0127
- Shahamati D, Akhavan NS, Rosenkranz SK. Postprandial inflammation in obesity: dietary determinants, adipose tissue dysfunction and the gut microbiome. Biomolecules. 2025;15(11):1516. Narrative review. https://doi.org/10.3390/biom15111516
- Aziz A, Adil MZ, Altaf M, Wang M, Cheong KL. Gastrointestinal tract remodeling by dietary polysaccharides: mechanistic insights in colitis. Foods. 2026;15(13):2267. Review, mechanistic and preclinical. https://doi.org/10.3390/foods15132267
This article is for general information and isn't medical advice. Ozzi is a dietary supplement and isn't intended to diagnose, treat, cure, or prevent any disease. Talk to your doctor before changing your diet or starting a supplement, especially if you manage a metabolic or digestive condition.
